Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19)

Running title: Diagnostic tools for COVID-19 infections

Pingping Zhang[1,2,#], Qi Gao[2,3,#], Tang Wang[4,#], Yuehua Ke[5], Fei Mo[6,7], Ruizhong Jia[5], Wanbing Liu[8], Lei Liu[8], Shangen Zheng[8], Yuzhen Liu[9], Luping Li[10], Yao Wang[11], Lei Xu[2,3], Kun Hao[2,3], Ruifu Yang[1,2,$], Shiyue Li[4,*], Changqing Lin[2,3,*], Yong Zhao[1,2,*]

[1] State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P. R. China

[2] Beijing Key Laboratory of POCT for Bioemergency and Clinic (No. BZ0329), Beijing 100071, P. R. China

[3] Beijing Hotgen Biotechnology Inc., Beijing 100071, P. R. China

[4] Wuhan University School of Health Sciences, P. R. China

[5] Huoshenshan Hospital, Wuhan, P. R. China

[6] Center for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, P. R. China

[7] Department of Basic Clinical Laboratory Medicine, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang 550004, P. R. China

[8] General Hospital of Central Threater Command of the PLA, Wuhan, P. R. China

[9] Shijiazhuang Fifth Hospital, Shijiazhuang 050023, P. R. China

[10] The Sixth People's Hospital of Shenyang, P. R. China

[11] Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking

Union Medical College, Chinese Academy of Medical Sciences, P. R. China

[#] These authors contributed equally to this work.

[$] Senior author

*Corresponding authors:

Yong Zhao: zhaoyong179@139.com

Changqing Lin: changqing.lin@hotgen.com.cn

Shiyue Li: lsywhd@sina.com

Abstract

Background: The colloidal gold immunochromatography assay (GICA) is a rapid

diagnostic tool for novel coronavirus disease 2019 (COVID-19) infections. However,

with significant numbers of false negatives, improvements to GICA are needed.

Methods: Six recombinant HCoV-19 nucleocapsid and spike proteins were prepared

and evaluated. The optimal proteins were employed to develop a sandwich-format

GICA strip to detect total antibodies (IgM and IgG) against HCoV-19. GICA's

performance was assessed with comparison of viral RNA detection.

Results: Recombinant HCoV-19 proteins were obtained, including three

prokaryotically expressed rN, rN1, rN2 nucleocapsid proteins, and three

eukaryotically expressed rS1, rS-RBD, rS-RBD-mFc spike proteins. The recombinant

proteins with the highest ELISA titers (rS1 and rS-RBD-mFc) against

coronavirus-specific IgM and IgG were chosen for GICA development. The GICA

has a sensitivity and specificity of 86.89% (106/122) and 99.39% (656/660),

respectively. Furthermore, 65.63% (21/32) of the clinically confirmed but RT-PCR

negative samples were GICA positive.

Conclusions: The eukaryotically-expressed spike proteins (rS1and rS-RBD-mFc) are

more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19

serological diagnosis. The GICA sandwich used to detect total antibodies is a

powerful complement to the current standard RNA-based tests.

Keywords: HCoV-19 (SARS-CoV-2), Recombinant protein, Eukaryotic expression,

Serological diagnosis, Colloidal gold immunochromatography assay (GICA)

Introduction

The recent coronavirus disease 2019 (COVID-19) outbreak has been classified as a

global pandemic on March 12, 2020, which continues to pose a great threat to global

public health. The disease is caused by a novel coronavirus, called 2019-nCoV by the

World Health Organization at the beginning of the outbreak, and latterly, severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2) by the ICTV (International

Committee on Taxonomy of Viruses) [1]. However, this name is prone to confusion

with SARS-CoV, which emerged in 2003, and a suggestion for a distinct name was

proposed, human coronavirus 2019 (HCoV-19) [2]. This novel virus is potentially

more transmissible than SARS-CoV and other coronavirus [3], making early

diagnosis of it important for clinical treatment and disease control. However, the

current nucleic acid testing approach for HCoV-19 [4] carries a negligible

false-negative risk [5]. Serological assays are supposedly a powerful approach for

achieving timely diagnosis of COVID-19, as is nucleic acid testing, especially for

patients with undetectable viral RNA [6]. The serological assays used for early

diagnosis are mainly based on detecting specific antibodies against HCoV-19 in a

patient's serum and include the enzyme-linked immunosorbent assay (ELISA), the

colloidal gold immunochromatography assay (GICA) and the chemiluminescence

assay.

To develop a reliable serological assay, it is important to obtain suitable HCoV-19

antigens or related recombinant proteins. HCoV-19 is a β family coronavirus, with a

spike protein (S protein), envelope protein (E), membrane protein (M), and

nucleocapsid protein (N protein). Among them, the N-protein is the most abundant,

relatively conservative protein in coronaviruses; thus, it is often used as a diagnostic

antigen [7]. Our previous study showed that the antigenicity of the COOH terminus is

higher than that of the NH_2 terminus in the SARS-CoV N protein, and that the former

N protein fragment may have the same antigenicity as that seen with the full-length N

protein [8]. In contrast, the S protein is the common target when designing vaccines

based on neutralizing antibodies. It contains a receptor binding domain (S-RBD) in

the S1 subunit, which mediates receptor binding and membrane fusion [9, 10].

Recently, S-RBD from HCoV-19 was reported to have higher affinity than

SARS-CoV to angiotensin-converting enzyme 2, and also to lack cross-reactivity with

monoclonal antibodies against S-RBD from SARS-CoV [3], highlighting the potential

value of the S protein for diagnosing HCoV-19. As a transmembrane protein with

hydrophobic regions, the S protein is better prepared using a eukaryotic expression

system.

In the present study, we prepared six recombinant proteins based on the reported

HCoV-19 sequence (GenBank accession MN908947) [11]. Three recombinant N

proteins were obtained by prokaryotic expression, including the full-length

recombinant N protein (rN), NH_2 terminal (rN1) protein fragments, and COOH

terminal (rN2) fragments from this protein. Three recombinant S proteins were also

obtained by eukaryotic expression, including an S1 domain (rS1) fragment, the

receptor binding domain (rS-RBD), and S-RBD ligated to the Fc fragment from

mouse (rS-RBD-mFc). The recombinant proteins were evaluated using indirect

ELISA. Two recombinant proteins with the highest ELISA titers (rS1and

rS-RBD-mFc) were chosen to develop a sandwich-format GICA strip to detect total

antibodies (IgM and IgG) against HCoV-19. The performance of the GICA strip,

which was evaluated with 814 clinical samples, showed a high detection sensitivity

(86.89%) and specificity (99.39%) with samples from COVID-19-infected patients.

9 Materials and Methods

10 Ethics statement

This study was approved by the Medical Ethical Committee of Peking Union

Medical College Hospital (approval number 002285), General Hosptical of Central

Threater Command of the PLA (approval number 2020-003-1), and Shijiazhuang

Fifth Hospital (approval number 2020-002). Written informed consent from all the

patients was obtained, and all records and information on the patients were

anonymized.

17 Materials

DNA polymerase (2×Pfu MasterMix) was purchased from Beijing TransGen

Biotech (Beijing, China). T4 DNA ligase and Gibison Assembly kit were from New

England BioLabs Inc., (Ipswich, England). Eukaryotic vectors H293 and H293-Fc,

which were used for transient expression, were obtained from the Laboratory of

Protein Project, Beijing Institute of Biotechnology, China. FreeStyle[TM] 293 expression

medium, Opti-MEM® I (1×), a reduced serum medium, and 293 fectin[TM] reagents

were purchased from Invitrogen Inc., (CA, Carlsbad, USA). The Unique CDSystem

for protein purification was from Suzhou Inscinstech Co., Ltd. (Suzhou, China). The

DNA extraction/purification kit was from Beijing TransGen Biotech. Primer

construction and sequencing work were conducted by Beijing Tianyi Huiyuan Biotech

Ltd., and Beijing Biomed Biotech Ltd., respectively. GICA nitrocellulose (NC)

membranes were obtained from MilliporeSigma. (Saint Louis, MO, USA), glass fiber

and absorbent pads were from Shanghai Kinbio Tech. Co., Ltd. (Shanghai, China).

The gene sequences of the recombinant proteins were all derived from the RNA

sequence of HCoV-19 strain from Wuhan (GenBank accession MN908947). The

nucleotide positions of the gene sequences are rS1 (21602–23584), rS-RBD

(22514–23311), rN (28274–29530), rN1 (28274–28900), and rN2 (28901–29530).

The N, N1, and N2 gene cloning vectors were constructed by General Biosystems Co.,

Ltd (Anhui, China). The S1 DNA sequence was optimized and synthesized by

GenScript Co., Ltd (Nanjing, China). The vector and bacterial strains for prokaryotic

expression were pET28a, *E. coli* Rosetta or BL21(DE3).

Gene subcloning, eukaryotic expression vector construction, and protein

expression and purification of rS1, rS-RBD-mFc and rS-RBD

The full coding region, which was obtained by overlapping extension PCR using

primers containing restriction enzyme recognition sites (Table 1), was ligated to

HEK293 vectors after digestion. The recombinant plasmids were transformed into *E.*

coli DH5α, and bacterial colonies were selected on Luria-Bertani (LB) agar

containing ampicillin. Positive colonies were cultured in 500 μL LB liquid medium

for 2–4 h, and the resultant plasmids were extracted, PCR-verified, and sequenced.

Positive recombinant plasmids (210 μg each) and liposomes (280 μL) were diluted in

7 mL of opti-MEM medium for 5 min, respectively, mixed for 30 min and H293 cells

(1.2×10^6 /mL) were added. After culturing (120 rpm, 37°C with 5% CO_2, 3–4 days),

the cell supernatants collected by centrifugation were purified with a 0.44-μm filter

and the Unique CDSystem chromatography workstation. After column Protein A

balancing (10 column volumes) with phosphate-buffered saline (PBS), the cell

supernatants were placed under a flow rate of 2.0 ml/min, and then washed and eluted

with PBS (five column volumes) and citric acid buffer (pH 3.0) to collect the purified

protein. For desalination, a 1/3 sample volume was applied to a G25 column

pre-balanced with PBS (5 column volumes), and each protein was collected after

column washes with PBS. Their purities were confirmed by sodium dodecyl

sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).

Gene subcloning, expression vector construction, protein expression and

purification of rN, rN1 and rN2

The N protein's full coding region was PCR amplified using primers containing

restriction enzyme recognition sites (Table 1). The restricted amplicons were ligated

into pET28a or pET32a using T4 DNA ligase. The recombinant plasmids were

transformed into *E. Coli* Rosetta or BL21 (DE3), and the bacterial colonies were

selected on LB agar containing kanamycin. Recombinant plasmids in the bacterial

colonies were extracted and confirmed as authentic by DNA sequencing. Protein

expression was induced for 5 h in positive bacterial colonies with 0.5 mM

isopropyl-D-thiogalactopyranoside (IPTG) at a starting optical density (OD) of 0.6.

After centrifugation, the supernatants and precipitation products from the lyzed

bacteria were analyzed by SDS-PAGE. The rN, rN1 and rN2 recombinant proteins

were produced by the bacteria harboring the recombinant plasmids via IPTG

induction in 2 L of LB medium (20°C, 200 × g, 10 h), and the bacteria were harvested

and lyzed by ultrasonication (300 W, 30 min). The supernatants were clarified by

centrifugation (10,000 × g, 20 min), filtrated (0.4-μm filter membrane), and run

through a 3 mL Ni Sepharose column with 30 ml lysis buffer, and then washed

extensively with PBS containing imidazole (20–80 mM gradient) to remove

non-specific proteins. The target proteins were eluted with PBS containing 250 mM

imidazole.

16   [Table 1]

Preliminary evaluation of recombinant proteins by ELISA

The recombinant proteins were initially evaluated by indirect ELISA. After coating

the wells with the prepared recombinant proteins, 50μL of serially diluted human

samples were added to the wells and mixed with 50μL of horseradish peroxidase

(HRP)-labeled goat anti-human IgM or IgG, followed by incubation (37°C, 60 min).

After the solution was removed and the wells had been washed with PBS buffer

containing Tween-20 five times, 50 µL of tetramethylbenzidine substrate was added to

the wells in the plate for 15 min. OD values were measured on a microplate reader

(450/630 nm), and recombinant proteins with high OD values for COVID-19 patient

serum and low OD reads for the negative control serum were used for all further

experiments.

ELISA plates coated with the six recombinant proteins were first tested with seven

negative sera from healthy people. Their average values plus two-fold standard

deviations (MEAN+2SD) were used as the cutoffs. However, they were not

completely equivalent for each protein and some were set at 0.2 when the calculated

values were below 0.2. Sera from two patients with COVID-19 were diluted at ratios

of 1:800, 1:400 and 1:100 for IgM detection, and ratio of 1:80, 1:40 and 1:20 for IgG

detection. The average value (MEAN) from the negative serum samples was set as the

background value, and the lowest antibody titer with a value higher than the cutoff

was set as the sensitivity level.

Preparing the GICA strip with recombinant proteins for antibody detection

Colloidal gold suspension was prepared by reducing gold chloride with citrate. The

colloidal gold was conjugated to recombinant protein rS-RBD. Briefly, 1 mg of

rS-RBD was added to 100 mL of the colloidal gold suspension. After a 30 min

reaction, conjugation was blocked using 10 mL of 10% bovine serum albumin (BSA)

for 15 min. The colloidal gold conjugate collected (centrifugation at 12,000 rpm, 30

min, 4°C) was resuspended in PBS containing 0.1% BSA and 0.1% Tween-20.

The colloidal gold and rS-RBD (0.5 mg/mL) conjugate was applied to a conjugate

pad (glass fiber) (30 µL/cm, dried at 37 °C, 3 h). Using a dispenser (XYZ3000;

BioDot, Irvine, CA), rS1 and the secondary polyclonal antibody (2 mg/mL) were

coated onto the nitrocellulose membrane as the test and control lines, respectively, at a

dispensing rate of 1.0 µL/cm. The membrane was then dried at 37 °C for 1 h. Finally,

the nitrocellulose membrane, conjugate pad, sample pad and the absorbent pads were

assembled and cut into 4-mm strips.

Evaluating the GICA strips

A positive serum sample was serially diluted with running buffer at a ratio of

1:10–1:320. The limit of detection of the GICA strip was determined using 100 µL of

the sample, and 0.9% NaCl was used as the blank control. The results could be

obtained by naked eyes after 5-10 min. Each test was repeated three times.

Additionally, 41 serially-diluted samples collected from healthy men were tested to

evaluate the specificity of the GICA strips.

Another 814 serum samples from patients suspected of harboring COVID-19

infections were collected from Huoshenshan Hospital, General Hospital of Central

Threater Command of the PLA, the Sixth People's Hospital of Shenyang, Peking

Union Medical College Hospital, and Shijiazhuang Fifth Hospital in China. All

samples were tested on the GICA strips, along with PCR tests on nasal/pharyngeal

swab for comparison. PCRs were performed with officially approved real-time PCR

(RT-PCR) kits.

Results

Acquisition of the six recombinant proteins

Through gene subcloning by overlapping extension PCR and ligation to the HEK

293 vector, the S1, S-RBD-mFc (containing the mouse Fc fragment) and S-RBD

recombinant plasmids were constructed and verified by PCR and sequencing (Figure

1A). Following lipofection, transient expression in eukaryotic HEK293 cells and

protein purification, highly pure rS1, rS-RBD-mFc and rS-RBD were obtained

(Figure 1D).

Through gene subcloning and ligation to the pET vector, recombinant N, N1 and

N2 plasmids were constructed and verified by PCR and sequencing (Figure 1B and C).

The rN, rN1 and rN2 expression products from IPTG induction at 37°C in *E. coli*

were identified in the culture supernatants and in the precipitates (Figure 1E and F),

so the induction temperature was lowered to 20°C, which increased the protein in the

supernatants significantly. The supernatant proteins were purified and used for

subsequent studies (Figure 1E and F). That the HCoV-19 N proteins were present in

the precipitates implies that their expression in *E. coli* may influence their accurate

folding or conformation, because the viral N protein may be conformationally

modified after transcription in human cells. Overall, six high-yield recombinant

proteins from HCoV-19 with high purities were obtained, as summarized in Table 2.

3   [Figure 1]

4   [Table 2]

Preliminary ELISA evaluation of recombinant proteins

Indirect ELISAs were used to preliminarily evaluate the six recombinant proteins.

Using serum samples from seven healthy people as the negative controls, serial

samples from two patients in the acute phase (<7 days after symptom onset) of

COVID-19 were detected. For the S proteins, the coefficient of variation (CV) for the

seven negative samples was 20%–30%. For the N proteins, the CV was 74%–92%,

resulting in a high cutoff value.

For IgM detection, all the S proteins had lower backgroud values and higher OD

values than those of the N proteins, as well as higher sentivities (1:800) (Figure 2A

and 2C). For IgG detection, rS-RBD-mFc had the highest sensitivity (1:80), while the

second highest sensivity (1:40) was attained by rS1, rS-RBD and rN (Figure 2B and

2D). Although with the same sensitivity and similar background, rS1 produced a

higher OD value than rS-RBD. The better performance of rS-RBD-mFc when

compared with rS-RBD may be related to the protein Fc fragments, which can

increase the half-life and stability for the RBD protein fragment from the S protein.

Overall, rS-RBD-mFc and rS1 were best suited for IgM and IgG detection.

The IgM-specific sensitivities for ELISA (from 1:100 to 1:800) are all higher than

those for IgG (1:20–1:80), mostly because the positive serial samples came from

patients during the acute phase of COVID-19 infection. Additionally, the antigenicity

of full-length rN was higher than that of fragments rN1 and rN2, which is consistent

with the findings from our previous study on SARS-CoV [8]. However, the higher

sensitivity of rN1 over rN2 suggests that the antigenicity of the protein fragment at

the NH_2 terminus of the N protein was higher than that at the COOH terminus, which

is the opposite result of our previous study on SARS-CoV [8].

9   [Figure 2]

Recombinant protein evaluation by GICA tests

As shown in Figure 3, a double-antigen sandwich-format GICA strip developed

with recombinant rS-RBD and rS1 proteins was used to detect total antibodies (IgM

and IgG) against HCoV-19 in serum samples. Positive results were observed at a

1:160 dilution of the patient serum, indicating that the GICA strip was able to detect

low- titer antibodies in serum. Moreover, several samples from patients infected with

influenza A, influenza B, respiratory syncytial virus, *Mycoplasma pneumoniae*, and

Chlamydia pneumoniae were all tested by GICA. No cross-reactions were observed

with these samples. An additional 41 serum samples from healthy people were all

negatively detected by the GICA strips, demonstrating good specificity for the

rS-RBD- and rS1-based serological methods.

21   [Figure 3]

GICA strip performances on serum samples

Altogether, 814 serum samples from HCoV-19-suspected patients were tested on GICA strips, including 122 patients confirmed to be RT-PCR positive, 660 confirmed to be RT-PCR negative, and 32 confirmed to be RT-PCR negative but clinically diagnosed by computed tomography (CT). The positive coincidence and negative coincidence rates between GICA and RT-PCR were 86.89% and 99.39%, respectively (Table 3). Moreover, among the 32 RT-PCR negative clinically diagnosed samples, 21 (65.63%) were detectable by GICA. This shows that GICA has a high coincidence rate with RT-PCR tests and also complements the PCR negative, clinically diagnosed cases, providing a potentially powerful serological tool for diagnosing COVID-19 in patients.

Discussion

Rapid detection methods are urgently required for the early diagnosis of patients with fever [10, 12, 13], and for pre-symptomatic or asymptomatic carriers infected with HCoV-19 [12, 14]. However, nucleic acid-based molecular diagnosis tools (e.g., real-time PCR and loop-mediated isothermal amplification), depend on there being a sufficient viral load in the patient's upper respiratory tract and reasonable sample quality. In the early infection stages, human antibodies, especially IgM, can reach a high level during the immune response to viral invasion. Therefore, serological testing

is important for early COVID-19 diagnosis, especially for patients with undetectable

viral RNA [10].

Selecting suitable recombinant HCoV-19 proteins for reliable serological assays is

crucial. Some cross-reactive N proteins from another coronavirus were serologically

investigated to meet the rapidly developing HCoV-19 emergency [9, 15]; however,

the divergent receptor binding protein spike gene in other CoVs [9], as well as the

high antigenicity of the receptor binding domain of HCoV-19 [3] emphasized the

necessity to research HCoV-19 antigens more comprehensively. Consequently, in the

present study, we prepared six recombinant proteins, including three S proteins (rS1,

rS-RBD, rS-RBD-mFc) and three N proteins (rN, rN1, rN2). Because the S protein is

a transmembrane protein, three S protein fragments were prepared using a eukaryotic

expression system, while three N proteins were prepared using a prokaryotic

expression system. Preliminary evaluation by indirect ELISA revealed that the three S

proteins were superior in performance to the three N proteins. Thus, it can be inferred

that the eukaryotically expressed HCOV-19 recombinant S protein is suitable for

detection of antibodies from COVID-19 patients for early diagnosis, and is superior to

the N protein prepared by prokaryotic expression. However, the antigenicity of S

proteins and that of the N proteins could not be confirmed in this study, because the

influence of prokaryotic expression method used to produce the N proteins is difficult

to predict. The prokaryotically expressed recombinant N proteins were all insoluble

precipitates, especially rN2, making it likely that their natural conformations were lost

or they were not normally modified. Thus, the N protein's antigenicity should be

studied after expression in a eukaryotic system in future.

GICA, a simple and rapid serological method, is especially suitable for timely

diagnosis and large-scale sample screening. A recent study showed that the sensitivity

of the total antibody (IgM and IgG) test is higher than that of the IgM or IgG test [16].

Therefore, we developed a sandwich-format GICA with rS1 and rS-RBD-mFc to

detect total antibodies in patient serum. The GICA tests were highly sensitive

(86.89%) and specific (99.39%), which should help with diagnosing COVID-19 in

RT-PCR-negative patients who are clinically confirmed COVID-19 positive by CT.

The detection sensitivity will be improved if we eliminate the sera from patients

within the 5 days of symptoms onset.

Conclusions

In the study, six recombinant HCoV-19 proteins were prepared and selected. It

showed that the eukaryotically-expressed spike proteins (rS1and rS-RBD-mFc) are

more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19

serological diagnosis. The provided recombinant proteins could be used for

development of serological diagnostic tools for COVID-19 infections. Here, A

sandwich-format GICA strip with the recombinant proteins was developed to detect

total antibodies (IgM and IgG) against HCoV-19. The assay was shown to be a rapid

(10 min), simple, and highly sensitive diagnostic tool, providing a potentially

powerful serological method for diagnosing COVID-19.

Notes

Acknowledgments

We thank the clinical study investigators and volunteers. We thank for our

collaborators in the Laboratory of Protein Project, Beijing Institute of Biotechnology,

for providing the eukaryotic vectors.

Financial support

Funding for this study was provided by The National Key Research and

Development Program of China (Grant No. 2018YFC1200502), and The National

Science and Technology Major Project (Grant No. 2018ZX10101003-002).

Potential conflicts of interest

All authors: No reported conflicts of interest. All authors have submitted the

ICMJE Form for Disclosure of Potential Conflicts of Interest.

No part of the information has previously been presented in any meetings.

Correspondence

Y. Z, Dr., Beijing Institute of Microbiology and Epidemiology, No. 20, Dongdajie

street, Fengtai district, Beijing 100071, P. R. China (zhaoyong179@139.com)

C. L., Mr., Beijing Key Laboratory of POCT for Bioemergency and Clinic (No.

BZ0329), Beijing 100071, P. R. China (changqing.lin@hotgen.com.cn)

S. L., Dr., Wuhan University School of Health Sciences, Wuhan 430071, P. R. China

(lsywhd@sina.com)

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol **2020**.

2. Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus. Lancet **2020**.

3. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science **2020**.

4. Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clinical Chemistry **2020**.

5. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect **2020**; 9:386-9.

6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet **2020**; 395:497-506.

7. Seo SH, Wang L, Smith R, Collisson EW. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol **1997**; 71:7889-94.

8. Chen Z, Pei D, Jiang L, et al. Antigenicity analysis of different regions of the

severe acute respiratory syndrome coronavirus nucleocapsid protein. Clin Chem

2004; 50:988-95.

9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new

coronavirus of probable bat origin. Nature **2020**.

10. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019

novel coronavirus: implications for virus origins and receptor binding. Lancet

2020; 395:565-74.

11. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory

disease in China. Nature **2020**.

12. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of

99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive

study. Lancet **2020**; 395:507-13.

13. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients

With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

2020.

14. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of

COVID-19. JAMA **2020**.

15. Wang N, Li SY, Yang XL, et al. Serological Evidence of Bat SARS-Related

Coronavirus Infection in Humans, China. Virol Sin **2018**; 33:104-7.

16. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients

of novel coronavirus disease 2019. medRxiv **2020**:2020.03.02.20030189.

Figure Captions

Figure 1. Gene fragments and purified recombinant HCoV-19 proteins analyzed by

agarose electrophoresis and SDS-PAGE. (A) PCR identification of S1 and

S-RBD-mFc gene fragments. (B) N gene fragment. (C) N2 gene fragment. (D)

SDS-PAGE for purified rS1 and rS-RBD-mFc. (E) SDS-PAGE for rN. Lanes 1 and 2

are the precipitatant and supernatant, respectively, from crude *E. coli* extracts

harboring the recombinant plasmid. Lanes 3–8: Ni Sepharose affinity column

purification. Lane 3 shows unbound proteins. Lanes 4–7: proteins washed from the

column using 10, 20, 60 and 80 mM imidazole. Lane 8 is rN eluted with 250 mM

imidazole. (F) SDS-PAGE for rN2. Lanes 1 and 2 are the supernatant and

precipitatant, respectively, from crude *E. coli* extracts harboring the recombinant

plasmid. Lanes 3– 9: Ni Sepharose affinity column purification. Lane 3 shows the

unpurified supernatant proteins. Lanes 4–7: Proteins washed from the column using

10, 20, 20 and 50 mM imidazole. Lanes 8–9: rN eluted in 250 mM imidazole.

Figure 2. Evaluation of recombinant HCOV-19 proteins by indirect ELISA on serum

samples. Serum samples from seven healthty people and two COVID-19 patients (P1

and P2) were used as negative controls and positive samples, respectively. (A) IgM

detection in serum samples by the   recombinant S1 domain protein fragment from

the HCoV-19 spike protein (rS1), the receptor binding domain of the S protein

(rS-RBD), and S-RBD ligated to the Fc fragment from mouse (rS-RBD-mFc)

following their expression in a eukaryotic system. (B) IgG detection in serum samples

using rS1, rS-RBD and rS-RBD-mFc proteins. (C) IgM detection in serum samples

using full-length recombinant nucleocapsid protein (rN), an NH2 recombinant

fragment from the N (rN1) or COOH (rN2) termini following their expression in a

prokaryotic system. (D) IgG detection in serum samples using rN, rN1 and rN2

proteins. Dashed lines, cutoff values.

Figure 3. (A) Schematic illustration of the sandwich-format GICA strip for IgM and

IgG antibody detection against HCoV-19. (B) Lower detection limit of the GICA strip,

as determined with serial dilutions of the positive serum. (C) Cross-reaction testing of

the GICA strip with other respiratory diseases.

1   **Figure 1**

6   **Figure 2**

Figure 3

A Serum (IgM/IgG)   Conjugation (gold-rS-RBD)   Test line (rS1)   Control line (Secondary Ab)

Sample pad   Conjugate pad   NC membrane   Absorbent pad

B

| 0 | 1:10 | 1:20 | 1:40 | 1:80 | 1:160 |
| - | + | + | + | + | + |

C

| 1 | 2 | 3 | 4 | 5 | 6 |
| + | - | - | - | - | - |

1-HCoV-19
2-Influenza A
3-Influenza B
4-RSV
5-*M. pneumoniae*
6-*C. pneumoniae*

1   **Tables**

2   **Table 1. Subcloning primers for preparation of the recombinant proteins**

Primer	Sequence
S1-F	GC<u>GAATTC</u>GCCGCCACCATGTTCGTGTTTCTGGTGCTGC
S1-R	GG<u>GGATCC</u>CTAGTGATGGTGATGGTGATGGTAGGAGGCAC AGATGCCGG
S-RBD-mFc-F	TC<u>CTTAAG</u>GGCGTGCAGTGCATGTTCTTGTTAACAACTAA ACGAACAATGTTTG
S-RBD-mFc-R	TC<u>GCTAGC</u>ACGTGCCCGCCGAGGAGAATTAG
S-RBD-F	TC<u>CTTAAG</u>GGCGTGCAGTGCAATATTACAAACTTGTGCCC TTTTGG
S-RBD-R	CT<u>GGATCC</u>CTAGTGATGGTGATGGTGATGCTCAAGTGTCT GTGGATCACGG
N-F	GAAGGAGATATA<u>CCATGG</u>GCATGTCTGATAATGGACCCCA
N-R	TGGTGGTGGTGGTG<u>CTCGAG</u>GGCCTGAGTTGAGTCAGCA
N1-F	CG<u>GGATCC</u>CGAATGTCTGATAATGGACC
N1-R	CCC<u>AAGCTT</u>TCTAGCAGGAGAAGTTCCCCTAC
N2-F	GAAGGAGATATA<u>CCATGG</u>GCATGGCTGGCAATGGCGGTGA TGCTGCTCTT
N2-R	CCG<u>CTCGAG</u>GGCCTGAGTTGAGTCAGCACTGCTC

3   Underlined letters: restriction enzyme recognition sites.

Table 2. Information of the prepared recombinant proteins

Protein	Tag[a]	Amino acid	MW[b] (kDa)	Expression	Strain[c]	Restriction site[d]
rS1-His	His	667	76.5	Eukaryotic	HEK 293	EcoR I/ BamH I
rS-RBD-mFc	His	501	63	Eukaryotic	HEK 293	Afl II/Nhe I
rS-RBD	His	259	30	Eukaryotic	HEK 293	Afl II/BamH I
rN	His	428	45	Prokaryotic (pET28a)	E.coli Rosetta	NcoI/XhoI
rN1	Sumo, His	273	47	Prokaryotic (pET28a)	E.coli BL21	BamHI/ HindIII
rN2	TrxA, His	210	43	Prokaryotic (pET32a)	E.coli BL21	NcoI/XhoI

[a] Protein tags. Sumo and TrxA tags are 18 and 20 kDa, respectively.

[b] Molecular weight of the recombinant protein including the tags.

[c] Strains used for engineering and protein expression

[d] Restriction enzyme recognition sites

1   **Table 3. GICA strip results of the serum samples**

Group	Total	GICA detection results (%)	
		Positive	**Negative**
RT-PCR Positive	122	106 (86.89%)	16 (13.11%)
RT-PCR Negative	660	4 (0.61%)	656 (99.39%)
Clinically confirmed	32	21 (65.63%)	11 (35.37%)

2
3
4